Days after Relyvrio’s FDA approval, Amylyx announces public offering to fund effort

Amylyx Pharmaceuticals is offering 6 million shares of common stock as part of a public offering, the company announced Wednesday morning.

Amylyx mentioned that it expects to grant underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The company is expected to raise between $167 million to $192 million as part of the offering.